Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids

被引：473

作者：

Deres, K ^{[1
]}

Schröder, CH

Paessens, A

Goldmann, S

Hacker, HJ

Weber, O

Krämer, T

Niewöhner, U

Pleiss, U

Stoltefuss, J

Graef, E

Koletzki, D

Masantschek, RNA

Reimann, A

Jaeger, R

Gross, R

Beckermann, B

Schlemmer, KH

Haebich, D

Rübsamen-Waigmann, H

机构：

[1] Bayer Res Ctr, Dept Virol, Wuppertal, Germany

[2] Bayer Res Ctr, Chem, Wuppertal, Germany

[3] Bayer Res Ctr, Isotope Chem, Wuppertal, Germany

[4] Bayer Res Ctr, Preclin Pharmakokinet, Wuppertal, Germany

[5] Bayer Res Ctr, Toxicol, Wuppertal, Germany

[6] Bayer Res Ctr, Safety Pharmacol, Wuppertal, Germany

[7] Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany

[8] Bayer Corp, Div Pharmaceut, West Haven, CT 06516 USA

来源：

SCIENCE | 2003年 / 299卷 / 5608期

关键词：

D O I：

10.1126/science.1077215

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 [理学]; 0710 [生物学]; 09 [农学];

摘要：

Chronic hepatitis B virus (HBV) infection is a major cause of liver disease. Only interferon-alpha and the nucleosidic inhibitors of the viral polymerase, 3TC and adefovir, are approved for therapy. However, these therapies are limited by the side effects of interferon and the substantial resistance of the virus to nucleosidic inhibitors. Potent new antiviral compounds suitable for monotherapy or combination therapy are highly desired. We describe non-nucleosidic inhibitors of HBV nucleocapsid maturation that possess in vitro and in vivo antiviral activity. These inhibitors have potential for future therapeutic regimens to combat chronic HBV infection.

引用

页码：893 / 896

页数：4

共 10 条

[1]

Delaney WE, 2001, ANTIVIR CHEM CHEMOTH, V12, P1

[2]

Development of resistance and perspectives for future therapies against hepatitis B infections:: Lessons to be learned from HIV [J].